Genocea Biosciences, Inc. (GNCA) News
Filter GNCA News Items
GNCA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GNCA News Highlights
- For GNCA, its 30 day story count is now at 2.
- Over the past 1 day, the trend for GNCA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest GNCA News From Around the Web
Below are the latest news stories about Genocea Biosciences Inc that investors may wish to consider to help them evaluate GNCA as an investment opportunity.
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET. |
The Petri Dish: Janssen inks two local deals, Biogen licenses new drugWhile some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings. |
Genocea to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. |
Needham Thinks Genocea Biosciences’ Stock is Going to RecoverIn a report released today, Gil Blum from Needham maintained a Buy rating on Genocea Biosciences (GNCA – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $1.13, close to its 52-week low of $0.92. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.25, a 470.9% upside from current levels. |
Genocea Biosciences Provides Corporate UpdateEnters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to explore the immunogenicity of neoantigens and t |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Thinking about buying stock in Ensysce Biosciences, Turkcell Iletisim Hizmetleri A.S., Genocea Biosciences, Inspira Technologies, or Biofrontera?NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENSC, TKC, GNCA, IINN, and BFRI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link. |
Reviewing Genocea Biosciences (NASDAQ:GNCA) and Inhibikase Therapeutics (NYSE:IKT)Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of recent ratings and price targets for Inhibikase Therapeutics [] |
State Street Corp Makes New $46,000 Investment in Genocea Biosciences, Inc. (NASDAQ:GNCA)State Street Corp purchased a new stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 19,684 shares of the biotechnology companys stock, valued at approximately $46,000. Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in [] |
Genocea to Present at the Stifel 2021 Virtual Healthcare ConferenceCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17 th at 1:20 PM ET. |